Sudeep Pharma Q2 FY27 Earnings Call — Analysis (NSE: SUDEEPPHRM)
Sudeep Pharma reported record Q2FY27 revenue of ₹196.7 Cr (+21% YoY) and EBITDA margin of 37.2% (+310bps YoY), driven by a 57% surge in Pharma Food Nutrition and receipt of US FDA approval for its 51,000 MT Nandesari facility.
Result quality: strong — Margin expansion. Management sentiment: optimistic.
The take
Q2FY27 Revenue from operations ₹196.7 Cr ( +21% YoY ) . Guidance cut . But missed — Battery materials commercial pipeline advancing .
Results
Revenue grew 21% YoY to ₹196.7 Cr; EBITDA rose 32% YoY to ₹73.2 Cr with EBITDA margin expanding to 37.2% (+310bps YoY); PAT rose 11% YoY to ₹51.8 Cr.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue from operations | ₹196.7 Cr | +21% | yoy · Q2FY27 · vs ₹162.7 Cr in Q2FY26 |
| Revenue from operations | ₹196.7 Cr | +24% | qoq · Q2FY27 · vs ₹158.3 Cr in Q1FY27 |
| EBITDA | ₹73.2 Cr | +32% | yoy · Q2FY27 · vs ₹55.5 Cr in Q2FY26 |
| EBITDA margin | 37.2% | +310bps | yoy · Q2FY27 · vs 34.1% in Q2FY26 |
| Profit After Tax (PAT) | ₹51.8 Cr | +11% | yoy · Q2FY27 · vs ₹46.8 Cr in Q2FY26 |
| Gross Margin | 64.7% | +220bps | yoy · Q2FY27 · vs 62.5% in Q2FY26 |
| PFN Segment Revenue | ₹142 Cr | +57% | yoy · Q2FY27 · contributed ~72% of consolidated revenue |
| Specialty Ingredients Revenue | ₹54 Cr | -25% | yoy · Q2FY27 · impacted by pause in Government Fortified Rice procurement |
| H1 FY27 Revenue from operations | ₹355 Cr | +23% | yoy · H1FY27 · vs ₹287.6 Cr in H1FY26 |
| H1 FY27 EBITDA | ₹128.1 Cr | +29% | yoy · H1FY27 · vs ₹99.3 Cr in H1FY26; 36.1% margin |
| H1 FY27 PAT | ₹92.4 Cr | +18% | yoy · H1FY27 · vs ₹78 Cr in H1FY26; 25.22% margin |
| Net Debt | ₹72.5 Cr | point_in_time · H1FY27 · 30-Sep-2026; 0.07x net debt-to-equity | |
| Net Working Capital Days | 214 days | point_in_time · H1FY27 · 30-Sep-2026; stable vs Mar-26 |
Guidance
Management targets commercial commissioning of Phase 1 Dahej battery-grade iron phosphate facility (25,000 MT) by April 2027 with binding offtake contracts expected in Q4FY27, alongside scaling Nandesari greenfield supplies starting Q4FY27.
Key themes
Capacity additions, FDA validation, and battery materials expansion
Operational commentary
- Received US FDA approval for the 51,000 MT greenfield facility at Nandesari; customer qualifications are underway with commercial supplies expected in H2 FY27 / Q4 FY27.
- Battery Materials (SAM) Dahej project on schedule for April 2027 Phase 1 commissioning (25,000 MT battery-grade iron phosphate); firm binding offtake agreements expected to be finalized in Q4 FY27.
- AbsorBis / MaxZobis (Magnesium bisglycinate) product category realizes 2-3x average PFN realization; expected to become a top-3 PFN revenue contributor (>₹100 Cr) within 2-3 years.
- Specialty Ingredients segment saw a 25% YoY decline due to temporary pause in Government of India Fortified Rice procurement (~20-25% of annual segment revenue); offset pipeline secured across infant nutrition and dietary supplements for Q3/Q4.
- Absorbed ~₹8 Cr in elevated sea freight and distribution expenses in Q2 FY27 without passing on to customers.
- Purified phosphoric acid prices increased, but strategic raw material inventory buffers protected gross margins in Q2 with continued support into Q3.
Analyst Q&A
Q. Can management quantify the proportion of Phase 1 battery material capacity currently under binding offtake contracts?
Refrained from disclosing specific volume breakdowns today, noting concrete binding agreements and customer breakdowns will be disclosed in Q4 FY27.
Q. What is the expected EBITDA margin and capex outlay for the brownfield expansion from 100,000 to 200,000 MT in battery materials?
Declined to guide specific EBITDA margins or capex amounts for battery materials, citing competitive sensitivity, but reiterated a ~3x asset turnover target and ROCE profile matching historical performance.
Q. What caused the sharp margin divergence between PFN (41%) and Specialty Ingredients (28%) in Q2?
Attributed to negative operating leverage from the absence of the high-realization fortified rice program and drag at NSS, whereas PFN benefited from operating leverage and higher phosphate/bisglycinate allocations.
Q. How does Sudeep defend against potential Indian competitors entering battery-grade iron phosphate?
Explained proprietary green chemistry process developed over 4 years reducing effluent by 90% and solid waste by 95%, overcoming India's strict environmental limits that constrain conventional high-effluent Chinese routes, along with 30-year upstream sourcing access in phosphoric acid.
Research and educational content only. Not investment advice.